JPMorgan Chase & Co. (JPM) - Bullish ResMed (RMD) Coverage Initiation Bucks Trend Of Divergent Sell-Side Valuation Shifts - Borrow Rate

Live News

As of May 3, 2026, aggregated sell-side data shows the consensus 12-month fair value estimate for ResMed has been revised 2.8% lower to $288.21, down from a prior forecast of $296.53, reflecting modestly more cautious valuation assumptions across a subset of the analyst community. Recent sell-side actions include a $45 price target cut from Evercore ISI in late April 2026, followed by downward adjustments from Baird, KeyBanc, and Citi, which trimmed its target by $5 after previously raising it b JPMorgan Chase & Co. (JPM) - Bullish ResMed (RMD) Coverage Initiation Bucks Trend Of Divergent Sell-Side Valuation ShiftsWhile data access has improved, interpretation remains crucial. Traders may observe similar metrics but draw different conclusions depending on their strategy, risk tolerance, and market experience. Developing analytical skills is as important as having access to data.The increasing availability of commodity data allows equity traders to track potential supply chain effects. Shifts in raw material prices often precede broader market movements.JPMorgan Chase & Co. (JPM) - Bullish ResMed (RMD) Coverage Initiation Bucks Trend Of Divergent Sell-Side Valuation ShiftsA systematic approach to portfolio allocation helps balance risk and reward. Investors who diversify across sectors, asset classes, and geographies often reduce the impact of market shocks and improve the consistency of returns over time.

Key Highlights

The 2.8% downward adjustment to consensus fair value for RMD is driven by incremental tweaks to core financial model assumptions, including a 27 bps cut to forward revenue growth forecasts (from 7.87% to 7.60%), a 25 bps reduction to projected net profit margins (to 28.82%), a 0.31x cut to the forward P/E valuation multiple (to 26.49x), and a 2 bps increase to the weighted average cost of capital (discount rate, to 7.85%), reflecting marginally higher perceived operational and market risk. JPMor JPMorgan Chase & Co. (JPM) - Bullish ResMed (RMD) Coverage Initiation Bucks Trend Of Divergent Sell-Side Valuation ShiftsAccess to multiple perspectives can help refine investment strategies. Traders who consult different data sources often avoid relying on a single signal, reducing the risk of following false trends.Investors these days increasingly rely on real-time updates to understand market dynamics. By monitoring global indices and commodity prices simultaneously, they can capture short-term movements more effectively. Combining this with historical trends allows for a more balanced perspective on potential risks and opportunities.JPMorgan Chase & Co. (JPM) - Bullish ResMed (RMD) Coverage Initiation Bucks Trend Of Divergent Sell-Side Valuation ShiftsSome investors prefer structured dashboards that consolidate various indicators into one interface. This approach reduces the need to switch between platforms and improves overall workflow efficiency.

Expert Insights

JPMorgan’s bullish stance on RMD represents a high-conviction contrarian signal that underscores the firm’s broader overweight rating on the global healthcare equipment sector, which it projects will outperform the S&P 500 by 7% to 9% over the next 12 months as secular defensive growth stocks benefit from expected monetary policy easing in the second half of 2026. JPM’s research team notes that recent downward valuation cuts from peers are largely tied to short-term, transitory headwinds, rather than erosion of RMD’s long-term structural growth moat. The global respiratory care market is set to expand at a 6.2% compound annual growth rate through 2030, fueled by rising global prevalence of undiagnosed sleep apnea and chronic obstructive pulmonary disease, and JPM estimates RMD will capture more than 40% of that incremental demand due to its integrated care ecosystem that creates high switching costs for both care providers and patients. RMD’s cloud-connected platform segment now counts more than 12 million active global users, generating 22% of total annual revenue at gross margins of 46% (1,200 bps above its core hardware segment), and JPM forecasts this segment will grow at a 12% annual clip through 2029, lifting overall group net margins by 180 bps over the same period. The cautious stance from firms including Evercore ISI and Baird is tied to concerns over emerging oral appliance therapy competition for mild-to-moderate sleep apnea patients, which these firms estimate could cut RMD’s hardware sales by 3% to 5% over the next two years, as well as 2026 CMS reimbursement cuts for home respiratory equipment that are expected to weigh on near-term top-line growth. However, JPM’s analysis puts expected market share loss from competing therapies at less than 1% annually, as RMD’s integrated remote monitoring capabilities create sticky customer relationships that offset risk of substitution. The upcoming Indiana distribution center is also expected to deliver $13 million to $16 million in annual logistics cost savings once fully operational, offsetting roughly 40% of the projected reimbursement headwinds in 2027, a catalyst that most conservative analysts have not yet priced into their valuation models. For investors, the mixed analyst signals are likely to drive short-term price volatility, but create an attractive entry point for long-term holders focused on RMD’s durable secular growth trajectory, aligned with JPM’s bullish thesis. (Total word count: 1172) JPMorgan Chase & Co. (JPM) - Bullish ResMed (RMD) Coverage Initiation Bucks Trend Of Divergent Sell-Side Valuation ShiftsCombining technical and fundamental analysis allows for a more holistic view. Market patterns and underlying financials both contribute to informed decisions.Real-time monitoring of multiple asset classes can help traders manage risk more effectively. By understanding how commodities, currencies, and equities interact, investors can create hedging strategies or adjust their positions quickly.JPMorgan Chase & Co. (JPM) - Bullish ResMed (RMD) Coverage Initiation Bucks Trend Of Divergent Sell-Side Valuation ShiftsDiversification in analysis methods can reduce the risk of error. Using multiple perspectives improves reliability.